JAGX Valuation
Jaguar Health Inc
$
5.570
- Overview
- Forecast
- Valuation
JAGX Relative Valuation
JAGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, JAGX is overvalued; if below, it's undervalued.
Historical Valuation
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.40
P/B
Median3y
1.82
Median5y
4.69
-851.90
FCF Yield
Median3y
-342.42
Median5y
-235.28
Competitors Valuation Multiple
The average P/S ratio for JAGX's competitors is 0.29, providing a benchmark for relative valuation. Jaguar Health Inc Corp (JAGX) exhibits a P/S ratio of 0.22, which is -23.68% above the industry average. Given its robust revenue growth of 52.57%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
People Also Watch
BVS
Bioventus Inc
7.480
USD
-1.19%
LVWR
LiveWire Group Inc
2.360
USD
+3.96%
YEXT
Yext Inc
5.890
USD
-0.34%
ADSE
Ads-Tec Energy PLC
12.190
USD
+2.01%
TYRA
Tyra Biosciences Inc
7.960
USD
+5.43%
GCT
GigaCloud Technology Inc
11.700
USD
+1.04%
TSAT
Telesat Corp
17.370
USD
-0.80%
IE
Ivanhoe Electric Inc
5.360
USD
+7.20%
VTS
Vitesse Energy Inc
20.420
USD
+3.44%
ICLK
iClick Interactive Asia Group Ltd
9.240
USD
+10.00%
FAQ
Is Jaguar Health Inc (JAGX) currently overvalued or undervalued?
Jaguar Health Inc (JAGX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.22 is considered Fairly compared with the five-year average of 3.53. The fair price of Jaguar Health Inc (JAGX) is between to according to relative valuation methord.
What is Jaguar Health Inc (JAGX) fair value?
How does JAGX's valuation metrics compare to the industry average?
What is the current P/B ratio for Jaguar Health Inc (JAGX) as of Apr 14 2025?
What is the current FCF Yield for Jaguar Health Inc (JAGX) as of Apr 14 2025?
What is the current Forward P/E ratio for Jaguar Health Inc (JAGX) as of Apr 14 2025?